87 related articles for article (PubMed ID: 24073856)
21. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
Sarvi S; Mackinnon AC; Avlonitis N; Bradley M; Rintoul RC; Rassl DM; Wang W; Forbes SJ; Gregory CD; Sethi T
Cancer Res; 2014 Mar; 74(5):1554-65. PubMed ID: 24436149
[TBL] [Abstract][Full Text] [Related]
22. CD133+ subpopulation of the HT1080 human fibrosarcoma cell line exhibits cancer stem-like characteristics.
Feng BH; Liu AG; Gu WG; Deng L; Cheng XG; Tong TJ; Zhang HZ
Oncol Rep; 2013 Aug; 30(2):815-23. PubMed ID: 23708735
[TBL] [Abstract][Full Text] [Related]
23. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.
Banerjee S; Nomura A; Sangwan V; Chugh R; Dudeja V; Vickers SM; Saluja A
Clin Cancer Res; 2014 May; 20(9):2388-99. PubMed ID: 24634377
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.
Li W; Reeb AN; Sewell WA; Elhomsy G; Lin RY
PLoS One; 2013; 8(5):e65095. PubMed ID: 23724124
[TBL] [Abstract][Full Text] [Related]
25. Local bystander effect induces dormancy in human medullary thyroid carcinoma model in vivo.
Kucerova L; Feketeova L; Matuskova M; Kozovska Z; Janega P; Babal P; Poturnajova M
Cancer Lett; 2013 Jul; 335(2):299-305. PubMed ID: 23485727
[TBL] [Abstract][Full Text] [Related]
26. Stem cells and cancer stem-like cells in endocrine tissues.
Lloyd RV; Hardin H; Montemayor-Garcia C; Rotondo F; Syro LV; Horvath E; Kovacs K
Endocr Pathol; 2013 Mar; 24(1):1-10. PubMed ID: 23435637
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells.
Matuskova M; Baranovicova L; Kozovska Z; Durinikova E; Pastorakova A; Hunakova L; Waczulikova I; Nencka R; Kucerova L
J Gene Med; 2012 Dec; 14(12):776-87. PubMed ID: 23150190
[TBL] [Abstract][Full Text] [Related]
28. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
29. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Ke CC; Liu RS; Yang AH; Liu CS; Chi CW; Tseng LM; Tsai YF; Ho JH; Lee CH; Lee OK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):61-71. PubMed ID: 23081821
[TBL] [Abstract][Full Text] [Related]
30. Cancer stem cell definitions and terminology: the devil is in the details.
Valent P; Bonnet D; De Maria R; Lapidot T; Copland M; Melo JV; Chomienne C; Ishikawa F; Schuringa JJ; Stassi G; Huntly B; Herrmann H; Soulier J; Roesch A; Schuurhuis GJ; Wöhrer S; Arock M; Zuber J; Cerny-Reiterer S; Johnsen HE; Andreeff M; Eaves C
Nat Rev Cancer; 2012 Nov; 12(11):767-75. PubMed ID: 23051844
[TBL] [Abstract][Full Text] [Related]
31. Thyroid cancer development and progression: emerging role of cancer stem cells.
Malaguarnera R; Morcavallo A; Giuliano S; Belfiore A
Minerva Endocrinol; 2012 Jun; 37(2):103-15. PubMed ID: 22691885
[TBL] [Abstract][Full Text] [Related]
32. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
[TBL] [Abstract][Full Text] [Related]
33. Cancer stem cells: an evolving concept.
Nguyen LV; Vanner R; Dirks P; Eaves CJ
Nat Rev Cancer; 2012 Jan; 12(2):133-43. PubMed ID: 22237392
[TBL] [Abstract][Full Text] [Related]
34. Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer.
Miyatani T; Kurita N; Utsunomiya T; Iwata T; Nishioka M; Yoshikawa K; Higashijima J; Kashihara H; Takasu C; Fukushima M; Shimada M
Cancer Lett; 2012 May; 318(2):199-205. PubMed ID: 22178656
[TBL] [Abstract][Full Text] [Related]
35. Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine.
Kucerova L; Matuskova M; Hlubinova K; Bohovic R; Feketeova L; Janega P; Babal P; Poturnajova M
Cancer Lett; 2011 Dec; 311(1):101-12. PubMed ID: 21824724
[TBL] [Abstract][Full Text] [Related]
36. Thyroid cancer stem cells.
Lin RY
Nat Rev Endocrinol; 2011 Jul; 7(10):609-16. PubMed ID: 21788969
[TBL] [Abstract][Full Text] [Related]
37. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis.
Yang K; Chen XZ; Zhang B; Yang C; Chen HN; Chen ZX; Zhou ZG; Chen JP; Hu JK
Int J Biol Markers; 2011; 26(3):173-80. PubMed ID: 21786247
[TBL] [Abstract][Full Text] [Related]
38. Clinical review: The emerging cell biology of thyroid stem cells.
Davies TF; Latif R; Minsky NC; Ma R
J Clin Endocrinol Metab; 2011 Sep; 96(9):2692-702. PubMed ID: 21778219
[TBL] [Abstract][Full Text] [Related]
39. 5-Fluorouracil pharmacogenomics: still rocking after all these years?
Scartozzi M; Maccaroni E; Giampieri R; Pistelli M; Bittoni A; Del Prete M; Berardi R; Cascinu S
Pharmacogenomics; 2011 Feb; 12(2):251-65. PubMed ID: 21332317
[TBL] [Abstract][Full Text] [Related]
40. Tumorigenic and metastatic activity of human thyroid cancer stem cells.
Todaro M; Iovino F; Eterno V; Cammareri P; Gambara G; Espina V; Gulotta G; Dieli F; Giordano S; De Maria R; Stassi G
Cancer Res; 2010 Nov; 70(21):8874-85. PubMed ID: 20959469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
